NASDAQ: QDEL · Life Sciences · 4 alerts · CIK 1906324
Share price
$10.21Close, Nov 16
Market cap
$701M
Shares outstanding
68.61MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All QuidelOrtho Corp filings on SEC EDGAR ↗
QuidelOrtho reported a net loss of $53.8 million for the third quarter of 2026, a significant improvement from the $733.0 million loss in the prior year which was driven by a large goodwill impairment. Total revenues decreased to $618.9 million from $699.9 million year-over-year, while the company's accumulated deficit grew to $1,234.5 million.
QuidelOrtho is undergoing a major restructuring to offset severe China headwinds and high leverage, shifting to a business-unit model while narrowing revenue guidance downward.
QuidelOrtho reported Q3 2026 revenue of $619 million, a 12% decrease year-over-year primarily due to lower sales in China and a softer respiratory season. The company also announced a major cost transformation and restructuring program expected to deliver over $80 million in annual savings by 2027, involving a shift to two focused business units: Core Diagnostics and Point of Care Diagnostics.
Term
Q3 2026
“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base. While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program.”
Brian J. Blaser, President and Chief Executive Officer